KALA BIO closed at $0.18 on Nov 4, up 2.95%, 99.9% below its 52-week closing high. Volume of 82.1K shares was 0.22× its 20-day average (below normal).
Split-adjusted performance: -51.1% over one month, -96.9% over six months, -99.5% over one year.
Short interest was 539.4K shares at the Oct 15 settlement, down 60.3% from the prior report (3.0% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KALAKALA BIO | $0.1781 | +2.95% | −96.9% | — | — | — | $3.4M | |
| SXTP60 Degrees Pharmaceuticals | $0.9563 | −5.32% | −42.4% | −32.5% | −1152.6% | — | $3.4M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
| JUNSJupiter Neurosciences | $2.46 | +1.23% | −91.0% | — | −9380.9% | — | $3.2M | Compare |
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | Compare |
| MBIOMustang Bio | $0.4138 | +1.07% | −44.6% | — | — | — | $3.1M | Compare |
| GRIGRI Bio | $1.43 | −7.14% | −39.4% | — | — | — | $3.1M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
| SILOSilo Pharma | $1.33 | +3.91% | −78.9% | −100.0% | — | — | $2.9M | Compare |
No recent articles focused on KALA BIO.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
